ABBV 63.27 Abbvie Inc. Common Stock $ABBV Hit a 52
Post# of 194
Posted On: 11/14/2014 10:05:24 AM
ABBV 63.27 Abbvie Inc. Common Stock $ABBV Hit a 52 week high of 63.99 Closing the day 09:45 at 63.27 -0.36 -0.57% With a day low of 63.22 and a total volume of 333,039.
ABBV Recent Posts: http://investorshangout.com/AbbVie-Inc-ABBV-90091/
ABBV Abbvie Inc. Common Stock Recent Headline News
Where Will Google Stock Be in 10 Years?
Leo Sun, The Motley Fool - Motley Fool - 1 hr 4 mins ago
Over the past decade, Google stock has soared over 500%, fueled by the growth in search and mobile devices. Google now controls 58% of the world's Internet searches and 85% of the mobile market via Android, and it continues to disrupt Microsoft'...
AMZN: 321.64 (+5.16), FB: 74.36 (+0.11), ABBV: 63.25 (-0.38), GOOGL: 553.63 (-2.81), GOOG: 543.15 (-2.23)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.69 (-0.38), GILD: 102.12 (-2.08), MRK: 59.34 (-0.20), ABBV: 63.25 (-0.38)
If Gilead Has The Ace, Is AbbVie Holding The Big Joker?
Shock Exchange - at Seeking Alpha - Fri Nov 14, 1:55AM CST
GILD: 102.12 (-2.08), ABBV: 63.25 (-0.38)
Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST
JNJ: 108.69 (-0.38), PFE: 30.47 (+0.05), ABBV: 63.25 (-0.38)
AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab)
PR Newswire - Thu Nov 13, 8:00AM CST
AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA® (adalimumab), rheumatologic diseases and investigational medicines will be presented at the upcoming 2014 American College of Rheumatology (ACR) Annual Meeting, November 14 - 19, in Boston. As a long-standing expert in the field of rheumatology with its experience with HUMIRA, AbbVie continues to build on its leadership with data focused on investigational medicines to create innovative solutions for rheumatologic diseases.
ABBV: 63.25 (-0.38)
Testosterone Sales Slump as Testosterone Lawsuit MDL Builds Momentum, Report Attorneys Handling National Testosterone Lawsuits
PRWeb - Thu Nov 13, 2:22AM CST
Lawyers providing legal representation for testosterone lawsuits report progress in the national multidistrict litigation for testosterone lawsuits; meanwhile, a major news source, Bloomberg Businessweek, reported on losses in the testosterone replacement therapy market. These attorneys offer timely testosterone lawsuit news updates and testosterone lawsuit case review at androgeltestosteronelawsuitcenter.com.
PFE: 30.47 (+0.05), ABBV: 63.25 (-0.38)
Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Wed Nov 12, 4:06PM CST
By Dr. Paul Nunzio De Santis (Pharm.D.) Entry: $9.86 10/2/14 Take Profits: $14.45 11/12/14 Hold 10-20% of profits into event for M&A upside. Achillion (NASDAQ: ACHN ) has been a stellar performer since we wrote about it on October 2nd- up...
ACHN: 13.87 (+0.38), MRK: 59.34 (-0.20), ABBV: 63.25 (-0.38)
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 196.51 (+0.30), JNJ: 108.69 (-0.38), GILD: 102.10 (-2.10), ABBV: 63.25 (-0.38)
Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie
Small Pharma Analyst - at Seeking Alpha - Wed Nov 12, 2:25PM CST
GILD: 102.10 (-2.10), ABBV: 63.25 (-0.38)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 196.51 (+0.30), ABBV: 63.25 (-0.38), SNY: 46.33 (-0.20), REGN: 399.88 (-2.75)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 112.37 (-0.35), GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), DNDN: 0.12 (-0.01), AMGN: 158.70 (-2.15), ABBV: 63.25 (-0.38), REGN: 399.88 (-2.75)
Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 141.97 (-0.74), ACT: 244.25 (+2.62), CBG: 32.45 (-0.24), HCP: 43.58 (-0.34), BCR: 164.69 (-0.90), PCG: 49.87 (+0.10), AMGN: 158.70 (-2.15), CB: 101.57 (+0.10), SRE: 109.21 (-0.30), PLD: 41.03 (-0.07), HSP: 57.46 (-0.63), TWX: 79.34 (+0.36), KIM: 24.63 (-0.11), CMI: 143.84 (-0.68), ALXN: 190.28 (-3.31), ESS: 200.29 (-0.23), ABBV: 63.25 (-0.38), CAT: 100.72 (-0.39), AAPL: 113.16 (+0.34)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 196.51 (+0.30), GILD: 102.12 (-2.08), ABBV: 63.25 (-0.38), BMY: 57.47 (-0.33)
Galapagos - AbbVie's Best Bet For Staying Market Leader In Rheumatoid Arthritis Post Humira?
SNJBiostoxx - at Seeking Alpha - Tue Nov 11, 2:45PM CST
ABBV: 63.25 (-0.38)
Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - Tue Nov 11, 1:04PM CST
SHPG: 201.15 (-1.27), PFE: 30.47 (+0.05), AZN: 72.95 (-1.58), ABBV: 63.25 (-0.38), WAG: 66.99 (+0.03)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), MRK: 59.34 (-0.20), ABBV: 63.25 (-0.38), BMY: 57.47 (-0.33)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.69 (-0.38), GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), CNAT: 7.05 (-0.10), MRK: 59.34 (-0.20), RGLS: 17.39 (-0.35), ABBV: 63.25 (-0.38), BMY: 57.47 (-0.33), ENTA: 43.20 (-0.02)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 112.37 (-0.35), GILD: 102.13 (-2.07), MRK: 59.34 (-0.20), DNDN: 0.12 (-0.01), AZN: 72.94 (-1.59), TEVA: 57.14 (-0.03), ABBV: 63.25 (-0.38), GSK: 45.64 (-0.02), BMY: 57.49 (-0.31), NVS: 93.52 (-0.86)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 379.56 (+0.15), YHOO: 50.69 (+0.19), AMZN: 321.65 (+5.17), BIIB: 311.18 (-6.80), VRTX: 112.37 (-0.35), FEYE: 32.95 (-0.39), LNKD: 230.94 (+1.17), EBAY: 54.23 (-0.14), GILD: 102.13 (-2.07), AMGN: 158.70 (-2.15), ABBV: 63.25 (-0.38), REGN: 399.88 (-2.75), CELG: 105.74 (-1.69)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.69 (-0.38), GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), CNAT: 7.05 (-0.10), MRK: 59.34 (-0.20), RGLS: 17.46 (-0.28), ABBV: 63.25 (-0.38), BMY: 57.49 (-0.31), ENTA: 43.20 (-0.02)
ABBV Recent Posts: http://investorshangout.com/AbbVie-Inc-ABBV-90091/
ABBV Abbvie Inc. Common Stock Recent Headline News
Where Will Google Stock Be in 10 Years?
Leo Sun, The Motley Fool - Motley Fool - 1 hr 4 mins ago
Over the past decade, Google stock has soared over 500%, fueled by the growth in search and mobile devices. Google now controls 58% of the world's Internet searches and 85% of the mobile market via Android, and it continues to disrupt Microsoft'...
AMZN: 321.64 (+5.16), FB: 74.36 (+0.11), ABBV: 63.25 (-0.38), GOOGL: 553.63 (-2.81), GOOG: 543.15 (-2.23)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.69 (-0.38), GILD: 102.12 (-2.08), MRK: 59.34 (-0.20), ABBV: 63.25 (-0.38)
If Gilead Has The Ace, Is AbbVie Holding The Big Joker?
Shock Exchange - at Seeking Alpha - Fri Nov 14, 1:55AM CST
GILD: 102.12 (-2.08), ABBV: 63.25 (-0.38)
Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST
JNJ: 108.69 (-0.38), PFE: 30.47 (+0.05), ABBV: 63.25 (-0.38)
AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab)
PR Newswire - Thu Nov 13, 8:00AM CST
AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA® (adalimumab), rheumatologic diseases and investigational medicines will be presented at the upcoming 2014 American College of Rheumatology (ACR) Annual Meeting, November 14 - 19, in Boston. As a long-standing expert in the field of rheumatology with its experience with HUMIRA, AbbVie continues to build on its leadership with data focused on investigational medicines to create innovative solutions for rheumatologic diseases.
ABBV: 63.25 (-0.38)
Testosterone Sales Slump as Testosterone Lawsuit MDL Builds Momentum, Report Attorneys Handling National Testosterone Lawsuits
PRWeb - Thu Nov 13, 2:22AM CST
Lawyers providing legal representation for testosterone lawsuits report progress in the national multidistrict litigation for testosterone lawsuits; meanwhile, a major news source, Bloomberg Businessweek, reported on losses in the testosterone replacement therapy market. These attorneys offer timely testosterone lawsuit news updates and testosterone lawsuit case review at androgeltestosteronelawsuitcenter.com.
PFE: 30.47 (+0.05), ABBV: 63.25 (-0.38)
Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Wed Nov 12, 4:06PM CST
By Dr. Paul Nunzio De Santis (Pharm.D.) Entry: $9.86 10/2/14 Take Profits: $14.45 11/12/14 Hold 10-20% of profits into event for M&A upside. Achillion (NASDAQ: ACHN ) has been a stellar performer since we wrote about it on October 2nd- up...
ACHN: 13.87 (+0.38), MRK: 59.34 (-0.20), ABBV: 63.25 (-0.38)
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 196.51 (+0.30), JNJ: 108.69 (-0.38), GILD: 102.10 (-2.10), ABBV: 63.25 (-0.38)
Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie
Small Pharma Analyst - at Seeking Alpha - Wed Nov 12, 2:25PM CST
GILD: 102.10 (-2.10), ABBV: 63.25 (-0.38)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 196.51 (+0.30), ABBV: 63.25 (-0.38), SNY: 46.33 (-0.20), REGN: 399.88 (-2.75)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 112.37 (-0.35), GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), DNDN: 0.12 (-0.01), AMGN: 158.70 (-2.15), ABBV: 63.25 (-0.38), REGN: 399.88 (-2.75)
Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 141.97 (-0.74), ACT: 244.25 (+2.62), CBG: 32.45 (-0.24), HCP: 43.58 (-0.34), BCR: 164.69 (-0.90), PCG: 49.87 (+0.10), AMGN: 158.70 (-2.15), CB: 101.57 (+0.10), SRE: 109.21 (-0.30), PLD: 41.03 (-0.07), HSP: 57.46 (-0.63), TWX: 79.34 (+0.36), KIM: 24.63 (-0.11), CMI: 143.84 (-0.68), ALXN: 190.28 (-3.31), ESS: 200.29 (-0.23), ABBV: 63.25 (-0.38), CAT: 100.72 (-0.39), AAPL: 113.16 (+0.34)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 196.51 (+0.30), GILD: 102.12 (-2.08), ABBV: 63.25 (-0.38), BMY: 57.47 (-0.33)
Galapagos - AbbVie's Best Bet For Staying Market Leader In Rheumatoid Arthritis Post Humira?
SNJBiostoxx - at Seeking Alpha - Tue Nov 11, 2:45PM CST
ABBV: 63.25 (-0.38)
Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - Tue Nov 11, 1:04PM CST
SHPG: 201.15 (-1.27), PFE: 30.47 (+0.05), AZN: 72.95 (-1.58), ABBV: 63.25 (-0.38), WAG: 66.99 (+0.03)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), MRK: 59.34 (-0.20), ABBV: 63.25 (-0.38), BMY: 57.47 (-0.33)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.69 (-0.38), GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), CNAT: 7.05 (-0.10), MRK: 59.34 (-0.20), RGLS: 17.39 (-0.35), ABBV: 63.25 (-0.38), BMY: 57.47 (-0.33), ENTA: 43.20 (-0.02)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 112.37 (-0.35), GILD: 102.13 (-2.07), MRK: 59.34 (-0.20), DNDN: 0.12 (-0.01), AZN: 72.94 (-1.59), TEVA: 57.14 (-0.03), ABBV: 63.25 (-0.38), GSK: 45.64 (-0.02), BMY: 57.49 (-0.31), NVS: 93.52 (-0.86)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 379.56 (+0.15), YHOO: 50.69 (+0.19), AMZN: 321.65 (+5.17), BIIB: 311.18 (-6.80), VRTX: 112.37 (-0.35), FEYE: 32.95 (-0.39), LNKD: 230.94 (+1.17), EBAY: 54.23 (-0.14), GILD: 102.13 (-2.07), AMGN: 158.70 (-2.15), ABBV: 63.25 (-0.38), REGN: 399.88 (-2.75), CELG: 105.74 (-1.69)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.69 (-0.38), GILD: 102.13 (-2.07), ACHN: 13.88 (+0.39), CNAT: 7.05 (-0.10), MRK: 59.34 (-0.20), RGLS: 17.46 (-0.28), ABBV: 63.25 (-0.38), BMY: 57.49 (-0.31), ENTA: 43.20 (-0.02)
(0)
(0)AbbVie Inc. (ABBV) Stock Research Links
Scroll down for more posts ▼